NCQA Heart/Stroke Recognition

We currently do not have any scheduled events.

OHS Research

Subscribe to NewsletterBlog

Clinical Research

At Orlando Heart Specialists we believe that today’s clinical trials provide the foundation for tomorrow’s clinical practice. We opened our research facility, Research One, in 2010 to assist our practice in providing access to cutting edge, academically focused “state of the art”, care and technologies to our patients. We participate in clinical trials that are patient focused and provide access to important new drugs and devices that help improve quality of life and survival in patients with cardiovascular disease.

Our patients are offered a variety of research opportunities that are aimed at understanding and improving upon existing treatments. Participation in clinical research is always voluntary. Declining a research study will never impact the care provided to our patients in any way.

Ongoing Clinical Trials

1.  Boehringer Ingelheim 1160.128   Pradaxa/GIS This study is to follow gastrointestinal symptoms for patients newly perscribed to Pradaxa.  If a GIS symptom occurs, patients will be randomized to either take Pradaxa within 30 minutes of food or to take a proton-pump inhibitor.

2. Boehringer Ingelhiem 1160.129 GLORIA-AF  This is a registry following various selected therapy choices for patients that have been recently diagnosed with atrial fibriallation.  Those patients who are taking Pradaxa will continued to be monitored during a specified time frame.

3. Bayer BAY59-7939 – X-VERT Trial This study is to determine the effects and safety of using Xarelto to prevent cardiovascular events with patients newly diagnosed with atrial fibrillation scheduled for cardioversion.

 

Completed Clinical Trials

Takeda Pharmaceuticals, Takada Examine Trial,  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to evaluate Cardiovascular Outcomes Following Treatment with Aloglipton in Addition to Standard of Care in Subject with Diabetes and Acute Coronary Syndrome , 2012

 

Gilead Sciences, A phase 4, Randomized,  Double-Blind, Placebo-Controlled, Cross-over Trial to Evaluate the Effects of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging. 2012